Using electronic monitoring to improve patient compliance in hematology treatments
Evaluation of the Impact of Electronic Monitoring on Patient Compliance in Hematology
This study is testing if using electronic monitoring can help people with blood disorders stick to their oral treatments better and improve their health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 110 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Private Hospital of Confluent, France Academic / other |
| Drugs / interventions | immunotherapy, CAR T, Chimeric Antigen Receptor |
| Locations | 3 sites (Amiens and 2 other locations) |
| Trial ID | NCT06713811 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of electronic monitoring in enhancing patient compliance with oral therapies for hematological conditions. It focuses on patients undergoing treatment for hemopathies, particularly those on long-term oral medications. By utilizing telemonitoring, the study aims to detect and manage adverse effects in real-time, thereby improving treatment adherence and potentially impacting patient outcomes. The study includes patients who have been on oral therapy for over six months and excludes those with certain conditions that may affect compliance.
Who should consider this trial
Good fit: Ideal candidates are patients with hemopathies who have been prescribed oral therapy for more than six months.
Not a fit: Patients expected to be on oral treatment for less than six months or those with certain active cancers or mental health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve treatment adherence and outcomes for patients with hematological disorders.
How similar studies have performed: Other studies have shown promise in using telemonitoring to improve treatment adherence, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Follow-up for haemopathy justifying initiation of oral therapy (one or more authorized molecules) for more than 6 months (1st line of treatment or more), * Intravenous treatment may be associated with it, in accordance with international recommendations (immunotherapy, corticosteroid therapy, other), * Patient affiliated to a social security scheme, * Patient having given written consent prior to any specific study procedure. Exclusion Criteria: * Oral treatment expected to last \< 6 months, * Cerebral tumor involvement, * Other active cancer \< 3 years, excluding skin, prostate and cervical carcinomas treated by surgery alone, * Pregnancy or breast-feeding * Persons deprived of their liberty, under guardianship or curatorship, * Dementia, mental alteration or psychiatric pathology that could compromise the patient's informed consent and/or compliance with the protocol and trial follow-up, * Patient unable to undergo protocol monitoring for psychological, social, family or geographical reasons. * No Internet connection * No telephone line
Where this trial is running
Amiens and 2 other locations
- Clinique de l'Europe — Amiens, France (Recruiting)
- Clinique de la Baie — Morlaix, France (Recruiting)
- Hôpital Privé du Confluent — Nantes, France (Recruiting)
Study contacts
- Study coordinator: Katell Le Dû, MD
- Email: dr.ledu@groupeconfluent.fr
- Phone: +33 6 15 24 60 67
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.